Navigation Links
US Patent and Trademark Office Allows CRi's Patent Application for Spectral Imaging of Deep Tissue
Date:11/28/2007

WOBURN, Mass., Nov. 28 /PRNewswire/ -- Cambridge Research & Instrumentation (CRi) announced today that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.

This method patent covers the use of multispectral imaging combined with spectral unmixing to greatly increase the signal-to-noise level of fluorophores in a living mammal. The unmixing of tissue autofluorescence is a critical component in achieving quantitative, highly sensitive results from fluorophores in vivo. The methodology covered by this allowance broadly covers multispectral imaging hardware and algorithm-based approaches, including the use of CRi's patented liquid crystal tunable filter (LCTF) technology and CRi's image acquisition and data analysis software packages.

"We are pleased to see recognition from the US Patent office for this fundamental patent that teaches quantitative multispectral image analysis of fluorescent samples in living mammals," says Peter Miller, Vice President and Chief Science Officer at CRi. "This patent allowance further strengthens our position in the area of in vivo imaging and further validates CRi's approach to providing customers with effective imaging solutions."

Increasing sophistication in the design and interrogation of biological models and the advent of novel fluorescent probes have lead to new demands on molecular imaging systems to deliver enhanced sensitivity, reliable quantification and the ability to resolve multiple simultaneous signals each separated from the ubiquitous autofluorescence background. Furthermore, orthotopic tumor and disease models are increasingly preferred over less biologically relevant subcutaneous xenografts. CRi has responded to these demands, and with this patent allowance, researchers performing in vivo fluorescence imaging are left with one reasonable choice. That choice is CRi.

CRi is a Boston-based biomedical imaging company providing innovative optical imaging solutions to our customers for more than 20 years. Our multidisciplinary team is dedicated to working with academic and commercial customers to provide high-value solutions. We provide comprehensive imaging and analysis solutions that enable the user to investigate and characterize biological phenotypes while preserving spatial context. With over 80 patents issued and pending, CRi's solution platforms encompass sub-cellular, cellular and whole animal applications. Our innovations are being utilized around the world to enable new breakthroughs in research, health and medicine. For more information visit our website at http://www.cri-inc.com or contact:

David Daniels, Ph.D.

Director of Marketing

CRi 35-B Cabot Road, Woburn, MA 01801 USA

Tel: 1-781-935-9099, extension 149

E-mail: ddaniels@cri-inc.com


'/>"/>
SOURCE Cambridge Research & Instrumentation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. Pressure BioSciences, Inc. Issued First Patent in Canada
4. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
5. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
6. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
7. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
8. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ComplianceOnline, the leading governance, risk ... its 3rd Annual Medical Device Summit 2017 venue and speaker lineup. The Summit will ... in Boston, MA. , The Omni Parker House Hotel, which is located at 60 ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, ... oncology and drug-delivery therapies, today announced that an ... and Drug Administration voted 11 to 0 that ... skin) injection was favorable for patients in the ... lymphoma and chronic lymphocytic leukemia. The FDA action ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, a privately owned ... travel award to noteworthy scientists who will be presenting research using ACEA Biosciences’ ... of awards are being given to two postdoctoral fellows studying pathogen capture by ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a company developing natural products ... through enhancement of the gut microbiota, today announced the closing of its first round ... York-based Sustainable Income Capital Management, LLC and a number of private investors. The company ...
Breaking Biology Technology:
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):